Latest news with #RegulatoryNews
Business Wire
a day ago
- Business
- Business Wire
TP Introduces ‘Future Forward' Strategy to Accelerate Transformation and Growth
PARIS--(BUSINESS WIRE)--Regulatory News: TP (Paris:TEP), a global leader in digital business services, unveils 'Future Forward,' its new strategic plan at a Capital Markets Day in New York City. 'Future Forward' is TP's strategic initiative to become a next-generation, AI-enabled company. This encompasses fusing cutting-edge technology with human expertise to expand growth and deliver long-term value. By intelligently orchestrating AI with human empathy, judgement and expertise, TP aims to create competitive advantages for its clients through digital integrated business services. TP is launching FAB (Foundational AI Backbone), a proprietary AI orchestration platform designed to seamlessly integrate artificial intelligence, human expertise, and automation at scale. FAB will underpin TP's three pillar growth strategy: growing the core business with AI: leveraging technology and AI to deliver enhanced client outcomes, strengthen value propositions, and accelerate growth. extending vertical plays: expanding industry-specific solutions, end-to-end AI-enabled offerings and scaling specialized services globally. unlocking new opportunities in AI: accelerating growth in markets across the AI value chain, focusing on data services, technology, consulting, and digital marketing. TP plans to significantly invest over the next three years to accelerate AI deployment supported by a strengthened leadership structure to drive execution. Together, these initiatives position TP to harness the full potential of its human and technological capabilities, expanding the Group's total addressable market, including new markets, scaling high-margin business models and delivering meaningful value to clients. Daniel Julien, Founder and CEO of TP, commented: ' TP's growth story has always been shaped by bold pivots at key moments of industry disruption. With each wave of change, we have adapted, transformed and won. We have consistently demonstrated our ability to lead through transformation, setting the pace in a market where we continue to outperform. With our new strategic plan, rooted in a powerful human-AI hybrid approach and a resilient business model powered by exceptional AI-ready teams and reinforced governance, we are well-positioned to achieve ambitious yet realistic financial goals and deliver long-term value for our shareholders.' Thomas Mackenbrock, Deputy CEO of TP, added: 'TP is a global leader in digital business services with a strong track record. To build on this foundation and strengthen our long-term leadership, we are accelerating the transformation of the Group by harnessing the full potential of artificial and human intelligence. Our new strategic plan 'Future Forward', is designed to strengthen our core services portfolio, extend our vertical plays and capture new opportunities along the AI value chain. Our goal is clear: accelerate growth, expand margins and generate substantial cash flow to support strategic investments and return value to shareholders. This is the TP of tomorrow: the preferred AI-enabled strategic partner, creating relentless competitive advantage for our clients.' Expanding capabilities through strategic partnerships and acquisitions TP is expanding its AI capabilities through strategic partnerships and acquisitions. The Group has launched an AI partnership program with planned investments of up to €100 million in 2025. This initiative has already led to collaborations with leading AI pioneers: Sanas, a real-time speech understanding company; Parloa, a leading AI agent management platform for customer service, and; Ema, a cutting-edge agentic AI platform. TP also announced today the acquisition of 'Agents Only', an AI-enabled crowdsourcing platform for on-demand highly skilled domain experts across the world. 'Agents Only' provides a flexible talent infrastructure for the AI era, sourcing and managing thousands of AI-literate annotators, data scientists, and domain specialists. This acquisition will enhance TP's access to certified professionals at scale, accelerating project delivery and improving service quality across data labeling, data annotation, and generative AI support activities. 'Agents Only' and other new AI solutions will be seamlessly integrated into the FAB platform to ensure scalability and speed to market. For additional information on the acquisition of Agents Only, please refer to the press release issued today, June 18, 2025, which can be found here. TP and Carnegie Mellon University forge alliance to accelerate applied research for AI -Human augmentation TP is joining forces with Carnegie Mellon University's world-renowned School of Computer Science to accelerate AI research and innovation. To highlight this collaboration, Professor Martial Hebert, Dean of the School of Computer Science at CMU, is joining TP executives for a fireside chat at the Group's Capital Markets Day, offering his perspective on the evolving landscape of AI. Medium-term outlook for 2028 TP announces the following financial objectives for the next three years (2026-2028): Returning to sustained mid-single digit like-for-like 1 revenue yearly growth with 4-6% in 2028 Recurring EBITA margin at ~15.5% in 2028, expected post AI transformation Generating cumulative net free cash flow of ~€3 billion including organic AI efforts incurred over 2026-2028 Capital allocation priorities over the period are as follows: Investing ~20% of the net free cash flow to accelerate investments in AI and transformation, including strategic partnerships and selective bolt-on acquisitions Further strengthening TP's balance sheet with high financial flexibility and targeting net debt leverage ratio of 1.2x EBITDA in 2028 Returning to shareholders ~50% of the net free cash flow or ~€1.5 billion, through dividends (dividend policy maintained) and share buybacks 1 At constant scope and exchange rates Capital Markets Day 2025 details At TP's Capital Markets Day, CEO Daniel Julien, Deputy CEO Thomas Mackenbrock and members of the management team will present the Group's strategic priorities and medium-term financial outlook. An AI technology showcase, featuring TP's AI solutions and TP's AI partners solutions, will be presented at the event for in-person attendees. The event begins at 9:00 am ET / 3:00 pm CET and can be viewed virtually here All the documentation related to the CMD is available on the Group's website ( Investor days: Events and publications | TP -------------------------- Disclaimer All forward-looking statements are based on TP management's present expectations of future events and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For a detailed description of these factors and uncertainties, please refer to the 'Risk Factors' section of our Universal Registration Document, available at TP undertakes no obligation to publicly update or revise any of these forward-looking statements. Indicative investor calendar Capital Markets Day: June 18, 2025 First-Half 2025 Results: July 31, 2025 Third-Quarter 2025 Revenue: November 5, 2025 ABOUT TELEPERFORMANCE GROUP Teleperformance (TEP – ISIN: FR0000051807 – Reuters: - Bloomberg: TEP FP), is a global leader in digital business services which consistently seeks to blend the best of advanced technology with human empathy to deliver enhanced customer care that is simpler, faster, and safer for the world's biggest brands and their customers. The Group's comprehensive, AI-powered service portfolio ranges from front office customer care to back-office functions, including operations consulting and high-value digital transformation services. It also offers a range of specialized services such as collections, interpreting and localization, visa and consular services, and recruitment process outsourcing services. The teams of multilingual, inspired, and passionate experts and advisors, spread in close to 100 countries, as well as the Group's local presence allows it to be a force of good in supporting communities, clients, and the environment. In 2024, Teleperformance reported consolidated revenue of €10,280 million (US$11 billion) and net profit of €523 million. Teleperformance shares are traded on the Euronext Paris market, Compartment A, and are eligible for the deferred settlement service. They are included in the following indices: CAC 40, STOXX 600, S&P Europe 350, MSCI Global Standard and Euronext Tech Leaders. In the area of corporate social responsibility, Teleperformance shares are included in the CAC 40 ESG since September 2022, the Euronext Vigeo Euro 120 index since 2015, the MSCI Europe ESG Leaders index since 2019, the FTSE4Good index since 2018 and the S&P Global 1200 ESG index since 2017. For more information:
Business Wire
4 days ago
- Business
- Business Wire
Eurofins: Purchases of Own Shares From June 9th to June 13th 2025
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Transaction details In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website:
Yahoo
13-06-2025
- Business
- Yahoo
Tikehau Capital: Disclosure of Shares Repurchases from 06 June 2025 to 12 June 2025
PARIS, June 13, 2025--(BUSINESS WIRE)--Regulatory News: In accordance with Article 5 of EU Regulation n° 596/2014 (Market Abuse Regulation), detailed information is available on the website of Tikehau Capital (Paris:TKO): Name of the issuer Issuer Identity Code (LEI) Trading Day ISIN Aggregated volume per day (number of shares) Weighted average price per day Market (MIC Code) TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 06/06/2025 FR0013230612 1,016 19.1754 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 09/06/2025 FR0013230612 463 19.1254 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 10/06/2025 FR0013230612 1,071 19.0114 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 11/06/2025 FR0013230612 892 19.0490 XPAR TIKEHAU CAPITAL 969500BY8TEU16U3SJ94 12/06/2025 FR0013230612 1,086 18.8606 XPAR TOTAL 4,528 19.0311 View source version on Contacts Tikehau Capital
Business Wire
13-06-2025
- Health
- Business Wire
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg ® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
LYON, France--(BUSINESS WIRE)--Regulatory News: 'The consistency between the real-world Early Access Program data and our pivotal ARES trial underscores Xervyteg®'s clinical benefit for patients with severe, treatment-resistant aGvHD,' said Dr. Gianfranco Pittari, Chief Medical Officer at MaaT Pharma. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that Professor Mohamad Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University, will present updated data for Xervyteg ® (MaaT013) in treating acute Graft-versus-Host Disease (aGvHD) under the Early Access Program (EAP) at the European Hematology Association (EHA) Annual Congress 2025. This independent EAP dataset further supports the efficacy and safety profile of Xervyteg ® previously shown in the pivotal ARES trial. It also confirms the breakthrough potential of Xervyteg ® for aGvHD patients with limited treatment options and it also serves as supportive data within the Marketing Authorization Application (MAA) recently submitted to the European Medicines Agency (EMA). Key highlights: aGvHD is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. The patients (N=173) treated in EAP previously failed 1 to 6 aGvHD systemic treatment lines and most had grade III (49%) or IV (38%) aGvHD. The real-world data presented underscores the favorable safety profile of Xervyteg ® the strong and durable responses, translating into increased overall survival: Gastrointestinal Overall Response Rate (GI-ORR) of 53% at D28, with Complete Response (CR) observed in 30% of patients; all-organ Overall Response Rate (ORR) was 50% with 26% CR. Response is maintained at D56 indicating a long-term disease control with a GI-ORR of 47% and an ORR considering all organs of 46%. Overall Survival (OS) in all patients was 55% at 6 months, 48% at 12 months, 44% at 24 months. Xervyteg ® displayed a good overall safety profile in the EAP population. OS was significantly higher in patients who responded to Xervyteg ® (MaaT013) compared to non-responders (69% versus 25% at 12 months, and 61% versus 25% at 24 months). Median survival in all patients was 312 days. In responder patients, median survival was 834 days vs 69 days in non-responders. A subset of patients (n=70) failing both steroid resistant (SR) and ruxolitinib resistant (RR) and thus resembling the cohort enrolled in the pivotal Phase 3 ARES trial (NCT04769895), exhibited a significant and consistent efficacy profile: At both Day 28 and Day 56, Xervyteg ® demonstrated durable efficacy in SR/RR aGvHD patients, with GI-ORRs of 57% and Complete Response (CR) observed in 44% of patients at D28 and 51% at D56. All-organs ORR was 54% with 41% CR at D28, and 55% with 48% CR at D56. OS was 55% at 6 months, 51% at 12 months, 40% at 24 months. OS was significantly higher in patients who responded to Xervyteg ® compared to non-responders (77% versus 14% at 12 months, and 59% versus 14% at 24 months). Median survival in all 70 patients was 445 days. In responder patients, median survival was 834 days vs 53 days in non-responders. The complete data may be found here. 'The consistency between the real-world Early Access Program data and our pivotal ARES trial underscores Xervyteg ® 's clinical benefit for patients with severe, treatment-resistant aGvHD,' said Dr. Gianfranco Pittari, PhD, Chief Medical Officer at MaaT Pharma. 'This is particularly meaningful for clinicians and patients, as it confirms the potential of microbiome therapies to deliver long-term survival benefits in a population with historically poor outcomes.' In comparison, historical data from Abedin et al. 2021 demonstrated that in a similar population of patients, i.e. third-line aGvHD patients receiving additional treatment after ruxolitinib failure, the median survival was only 28 days. 'Among patients who responded by Day 28, the majority achieved a complete resolution of aGvHD symptoms — a strong predictor of sustained disease control over time. The overall safety profile is favorable in this high-risk patient population,' outlines Professor Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University. Details of the Oral Presentation: Title: Pooled Fecal Allogeneic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in Europe Abstract number: S260 Presenting Author: Mohamad Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University Session title: s424 Stem cell transplantation - Session 2 Date & Time: 13/06/2025 (17:00 - 17:15 CEST) - Brown Hall 3 MaaT Pharma also presented a poster on the design of its ongoing Phase 2b trial (PHOEBUS) evaluating MaaT033 to enhance overall survival in allo-HSCT. This international, multi-center trial (NCT05762211) is the largest randomized controlled study to date of a microbiome-based therapy in oncology, enrolling up to 387 patients across 60 sites. --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. * France, Austria, Belgium, Canada, Germany, Italy, Lebanon, Spain, Sweden, Switzerland & USA
Yahoo
10-06-2025
- Business
- Yahoo
GeNeuro SA Announces an Extraordinary Shareholders' Meeting on June 30, 2025
GENEVA, June 10, 2025--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders' meeting on June 30, 2025. As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva Tribunal of First Instance on 26 May 2025. In this context, the Company is not in a position to finalize and present its audited annual accounts for the financial year ending 31 December 2024. Consequently, it cannot hold its Ordinary Annual General Meeting within six months of year-end, as required under Swiss corporate law. Pursuant to the Company's Articles of Association and applicable Swiss legal provisions, the mandates of the current members of the Board of Directors will expire on 30 June 2025. To ensure continuity of governance, the Extraordinary General Meeting has been convened to vote on the re-election of the Board members, of the Chairman, of the Remuneration Committee, and of the Independent Proxy until the next Annual General Meeting can be held. The notice to the meeting is published today in the Swiss Official Gazette of Commerce. About GeNeuro GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. For more information, visit: Disclaimer This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.. View source version on Contacts GeNeuro Jesús Martin-GarciaChairman and CEOinvestors@ Sign in to access your portfolio
